Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,282 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)
Regulatory Filings Classification · 90% confidence The document is a Korean stock exchange (KRX) regulatory disclosure titled '투자판단 관련 주요경영사항' (Material Management Matters for Investment Decisions) providing factual details on a clinical trial approval. It is not a full financial report, earnings release, management change notice, dividend notice, or any other specific category listed. It constitutes a regulatory announcement of material information that does not fit the more specialized categories, so it defaults to the general Regulatory Filings category.
2026-04-24 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 94% confidence The document is a ‘주식등의 대량보유상황보고서(일반)’ under Korean capital markets law, detailing significant shareholdings, percentage ownerships, changes in major share positions, and related parties. This matches a Major Shareholding Notification, not an AGM, earnings release or annual/quarterly report. Therefore, it should be classified as MRQ.
2026-04-22 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 92% confidence The document is titled “주요사항보고서(자기주식 취득 결정)” filed to the Financial Supervisory Service/Korea Exchange, detailing the company’s decision to acquire its own shares, including planned quantity, amount, period, and method of buyback. This clearly fits the “Transaction in Own Shares” category (share repurchase).
2026-04-22 Korean
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 임상 3상 시험계획 변경신청)
Regulatory Filings Classification · 87% confidence The document is a Korean stock exchange (KRX) disclosure titled “투자판단 관련 주요경영사항” outlining a clinical trial plan change for CTP51. It is neither a full financial report nor an investor presentation, earnings release, or specific corporate action like share issuance. It is a routine material event disclosure for investors, fitting the generic “Regulatory Filings” category (RNS).
2026-03-30 Korean
투자판단관련주요경영사항 (마이크로바이옴 장질환 신약 후보물질 Licensein 계약 체결)
Regulatory Filings Classification · 82% confidence The document is a corporate regulatory announcement disclosing a significant license-in contract for a new drug candidate. It does not present financial statements or earnings, nor is it an AGM presentation, management change, share issue, or specific financing round. It is a general material event announcement that does not fit any of the specialized categories. Therefore, it is best classified as a Regulatory Filing (RNS) under the fallback category.
2026-03-25 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 95% confidence The document is a corporate announcement detailing the change in the company’s Chief Executive Officers (대표이사), including the names before and after, reasons for change, effective dates, and brief bios of the new appointees. This matches the category for Board/Management Information (changes in board or senior management).
2026-03-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.